Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Santhera discloses new MC4 receptor antagonists

Aug. 6, 2010

Mipomersen lowers LDL-cholesterol in two phase III trials

Aug. 5, 2010

TM-38837 shows favorable safety and pharmacokinetics in healthy subjects

Aug. 5, 2010

Diamyd receives upfront payment from OMJP under Diamyd collaboration

Aug. 4, 2010

BioMarin reports topline phase II data on PEG-PAL in PKU

Aug. 3, 2010

Servier to develop and commercialize Osteologix's NBS-101 outside U.S.

Aug. 3, 2010

Astellas and Kotobuki disclose new SGLT-1 and SGLT-2 inhibitors

Aug. 3, 2010

Auspex Pharmaceuticals claims deuterated SGLT-2 inhibitors

Aug. 3, 2010

Daiichi Sankyo discovers novel CaS receptor antagonists

Aug. 2, 2010

FDA advises of adverse effects related to unintended exposure to Evamist

Aug. 2, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...